Drug
Suvorexant 10 mg
Suvorexant 10 mg is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
100%(1 trials)
Phase Distribution
Ph early_phase_1
1
25%
Ph phase_1
1
25%
Ph phase_2
1
25%
Ph phase_4
1
25%
Phase Distribution
2
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(1)
Other(1)
Detailed Status
unknown1
Completed1
Active, not recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Early Phase 11 (25.0%)
Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 41 (25.0%)
Trials by Status
unknown125%
completed125%
active_not_recruiting125%
recruiting125%
Recent Activity
2 active trials
Showing 4 of 4
recruitingphase_2
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
NCT07214207
active_not_recruitingearly_phase_1
A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study
NCT04273776
unknownphase_1
Targeting Orexin to Treat Nicotine Dependence
NCT03999099
completedphase_4
Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs
NCT03312517
Clinical Trials (4)
Showing 4 of 4 trials
NCT07214207Phase 2
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
NCT04273776Early Phase 1
A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study
NCT03999099Phase 1
Targeting Orexin to Treat Nicotine Dependence
NCT03312517Phase 4
Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4